Zoetis Inc.
Company Overview
Zoetis Inc. is a leading global animal health company, specializing in the discovery, development, manufacture, and commercialization of veterinary vaccines and medicines. With its headquarters located in Parsippany, New Jersey, USA, Zoetis operates in more than 100 countries, delivering a diverse portfolio of products and services to veterinarians and livestock farmers worldwide.
Location and Facilities
Zoetis boasts a strong global presence with manufacturing, research, and commercial operations located across the globe. Its main research facilities are based in the United States, with other significant international offices and production sites in countries such as Belgium and Brazil. Notably, Zoetis produces Dectomax-CA1 in Kalamazoo, Michigan, a crucial product for livestock health.
Financial Indicators
As of 2022, Zoetis reported a revenue of approximately $8.1 billion. The company has consistently demonstrated strong financial health and a robust growth trajectory in the animal health sector. With a market capitalization around $80 billion, Zoetis reflects significant market presence and strong investor confidence.
Important Company Events
A recent significant development for Zoetis is the conditional approval granted by the U.S. Department of Agriculture (USDA) for its avian influenza vaccine. This vaccine is designed to protect poultry from the avian flu virus, a major concern for poultry farmers and agricultural stability. This development underscores Zoetis' commitment to innovation in animal health and addressing emerging diseases.
Company Plans
Looking forward, Zoetis aims to expand its product offerings and strengthen its position in the veterinary vaccine market. The company focuses on sustainability and innovation, actively investing in research and development to discover new solutions that tackle global challenges in animal health. This includes expanding their vaccine portfolio to address various diseases affecting livestock.
Modified: 2025/10/22